• Blog
  • Long Acting Injectable Anti Psychotic Market Report

    Long Acting Injectable Anti Psychotic Market Report

    Long Acting Injectable Anti Psychotic Market Report
    Report code - SRHL275 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Long-Acting Injectable Anti-Psychotic Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on Long Acting Injectable Anti Psychotic Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Long Acting Injectable Anti Psychotic Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Long-Acting Injectable Anti-Psychotic Market is expected to grow from USD xx million in 2020 to USD xx million by 2026 at a CAGR of over x% during the forecast period.

    Figure: Global Long Acting Injectable Anti-Psychotic Market Size, 2020-2026 (USD Million)

    Long-Acting-Injectable-Anti-Psychotic-Market-Forecast

    Wish to know more about the market assumptions? Click here to get a free sample.

    What are Long-Acting Injectable Antipsychotics?

    Anti-psychotic is a type of medication primarily used to manage psychosis which includes hallucinations, delusion, and paranoia in various psychotic disorders. Long-acting injectable (LAI) antipsychotic is primarily used to treat patients having schizophrenia disorder. It can be taken every two to four weeks or every three months instead of consuming pills on daily basis.

    Key Players

    Key players operating in the global Long-Acting Injectable Anti-Psychotic Market are-

    • Johnson & Johnson (The U.S),
    • Eli Lily and Company (The U.S),
    • Alkeremes Public Limited Company (Ireland),
    • H. Lundbeck A/S (Denmark),
    • Pfizer Inc. (The U.S),
    • GlaxoSmithKline plc (UK),
    • Lupin Limited (India),
    • MedinCell S.A. (France),
    • Zogenix (The U.S), and
    • Durect Corporation (The U.S).

    Market Dynamics

    Rising demand for advanced healthcare solutions coupled with increasing health awareness is likely to add to the market growth substantially.

    • The growth of the global long-acting injectable anti-psychotic market is primarily driven by an increasing number of people suffering from schizophrenia. It is diagnosed more frequently in males as compared to females.
    • Growing preference for long-acting injectable anti-psychotics over oral medications for people suffering from mental disorders is likely to propel the market growth at a significant rate during the review period.
    • However, the side effects of taking long-acting injectable anti-psychotics are likely to affect the market growth negatively.

    Segment Analysis

    Application Trends

    Based on application, the market has been segmented into schizophrenia and others. The schizophrenia segment accounted for the largest market share in 2020 and is projected to grow at the fastest CAGR during the review period. The segment growth can be attributed to the rising incidence of people suffering from schizophrenia. Schizophrenia is a serious mental disorder in which people abnormally infer reality.

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020. The regional market growth can be attributed to the increasing number of people suffering from mental disorders coupled with expanding geriatric population and the presence of established healthcare infrastructure.  The market in Asia-Pacific is expected to register the fastest growth during the review period on account of rising consumer awareness and increasing spending on healthcare.

    COVID-19 Impact on Global Long-Acting Injectable Anti-Psychotic Market

    The covid-19 outbreak did not affect the growth of the long-acting injectable anti-psychotic market. The national healthcare organization in many European countries and the US allowed the ongoing usage of long-term injectable anti-psychotics for patients suffering from mental disorders and having a high-risk chronic illness. The majority of mental healthcare facilities allowed the continuation of visits as it is an essential clinical procedure.

    Critical Questions Answered in the Report

    • What are the key trends in the global long acting injectable anti-psychotic market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global long acting injectable anti-psychotic market?
    • What are the key strategies adopted by the major vendors to lead in the global long acting injectable anti-psychotic market?
    • What is the market share of the top vendors?

    Want to know the full scope of the report? Register Here

    Target Audience

    The following is a list of the customers that the Global Long-Acting Injectable Anti-Psychotic market aims to convert the most:

    • Long-acting injectable anti-psychotic manufacturers
    • Long-acting injectable anti-psychotic suppliers
    • Long-acting injectable anti-psychotic distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Johnson & Johnson (The U.S), Eli Lily and Company (The U.S), Alkeremes Public Limited Company (Ireland), H. Lundbeck A/S (Denmark), Pfizer Inc. (The U.S), GlaxoSmithKline plc (UK), Lupin Limited (India), MedinCell S.A. (France), Zogenix (The U.S) and Durect Corporation (The U.S) are among the key players in the long acting injectable anti-psychotic market.

    North America accounted for the largest share in the long acting injectable anti-psychotic market in 2020.

    Asia-pacific is expected to register the fastest growth in the long acting injectable anti-psychotic market in the coming years.

    The schizophrenia segment is expected to grow at the fastest CAGR in the long acting injectable anti-psychotic market in the years to come.

    Rising demand for advanced healthcare solutions coupled with increasing health awareness, increasing number of people suffering from schizophrenia are the factors driving the growth of long acting injectable anti-psychotic market.

    Long-acting injectable anti-psychotic manufacturers, Long-acting injectable anti-psychotic suppliers, Long-acting injectable anti-psychotic distributors, Organizations, Government bodies are the target audience in the long acting injectable anti-psychotic market.

    •